ARTICLES BY LOUIS GARGUILO

• Early CDMO Engagement For Cell Therapies? CellProthera's CEO Thinks Not

  5/14/2026

  Tokyo Institute of Technology. London Business School. ETH Zürich. What do these institutions – and a biotech based in Mulhouse, France – have in common? Matthieu de Kalbermatten, CEO of CellProthera. His international experience adds up to this: Build an internal quality (cGMP) organization; become the master of the processes you create for your therapy, before moving to external help; then select your CDMO carefully – maybe just prior to Phase III.

• Vaccine Platform Vs. CDMO Model: Outsourcing Lessons For All Biopharma

  5/11/2026
• Cell And Gene Therapy CDMOs: On The Path To $75 Billion in Services?

  4/30/2026

  Cell and gene therapy (CGT) developers – and thus their service providers – have had their share of ups and downs. But what do the promise and uneven realities of these therapies add up to in the development and manufacturing outsourcing sector? According to a Towards Healthcare report, despite the bumps in the road, in 2025 the global CGT CDMO market grew to $8.2 billion. What of future predictions? Here's a detailed analysis.

• The Long Road To U.S. Vaccine Manufacturing

  3/19/2026

  GeoVax CEO David Dodd sings the praises and is grateful for the program-enabling relationships he has in Europe. At the same time, he harbors lingering disappointment. From the outset of its formation, the biotech has desired to work with U.S.-based CDMOs.  But he says he will not give up. “One way or the other,” Dodd says, “GeoVax will have U.S.-based manufacturing.”

• Not So Fast Into The Night: Your Outsourcing Needs A Pause

  2/16/2026

  Barreling through the initial months of the year? Here’s a suggestion from Chief Editor Louis Garguilo to pump the breaks for a bit. Take one more glance in the rearview mirror to assess your current progress, reconfirm your pathway is your intended one. An outsourcing pause might pay off handsomely this year, and that’s because a lot happened last year on the supply-chain front. You made plans and formed expectations based on those trends and experiences. Are you currently abiding by those analyses? 

• Biopharma Manufacturing Outsourcing Is Flexible, Not Fractured

  8/21/2025

  An element of the 2025 BioPlan Associates annual report and survey took Chief Editor Louis Garguilo by surprise. The report intimates that biopharmaceutical manufacturing faces a fractured CDMO market. Despite solid data to back that assertion up, Garguilo presents a very different view, one based on what many readers have expressed.

• New Jersey Solutions For Cell And Gene Development And Manufacturing

  7/17/2020

  NJ's first university-based, cell-and-gene-therapy development and manufacturing innovation center for-hire was founded on the answers to three questions of the biopharma industry.

• U.S. Manufacturing On The Rise: Add Another CDMO To The Heartland

  3/16/2020

  Ascending U.S.-based CDMOs may exemplify a national taking back of our own supply-chain destiny. Now there’s another CDMO, Andelyn Biosciences, taking shape in Central Ohio, and targeting gene-therapy services.

• A Harvard Assist For Cell And Gene Bottlenecks

  1/27/2020

  Bottlenecks and backlogs in development and production of cell and gene therapies. Harvard to the rescue. Actually, Harvard with partners, such as companies familiar to Outsourced Pharma readers. But what will  go into the the $50 million Center for Advanced Biological Innovation and Manufacturing? We’ve got exclusive details.  

• Equipment You Need At Your Cell-And-Gene CDMO

  1/27/2020

  What equipment is essential at the CDMO assisting with your cell and gene therapy development and production? I’ve received some details via an investigation into Harvard’s Center for Advanced Biological Innovation and Manufacturing, and a discussion with the CEO & President of GE Healthcare Life Sciences.

• Straight Talk From BeiGene On Quality, Compliance, And Outsourcing

  1/26/2020

  It was time within our ruminations on China to speak directly with a quality executive at a drug developer and manufacturer based there. That’s now accomplished via a discussion with Diana Francis, Vice President, Quality & Compliance, BeiGene, Ltd., a biopharma some have dubbed as a potential “Genentech of China.” Francis spoke openly about her role, BeiGene’s global strategy, and outsourcing within and from China.